Dicerna Pharmaceuticals reported $-38578000 in EBITDA for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acceleron Pharma XLRN:US $ -62.63M 0.05M
Agenus AGEN:US $ -64.67M 25.03M
Alnylam Pharmaceuticals ALNY:US $ -134.35M 39.3M
Amgen AMGN:US $ 3188M 218M
Arrowhead Research ARWR:US $ -29868000 3.56M
Biogen BIIB:US $ 1147.6M 41.7M
Bluebird Bio BLUE:US $ -234.8M 9.32M
Dicerna Pharmaceuticals DRNA:US $ -38.58M 10.29M
Exelixis EXEL:US $ 126.68M 128.06M
Gilead Sciences GILD:US $ 2816M 669M
GlaxoSmithKline GSK:LN 2626M 584M
Immunogen IMGN:US $ -26.83M 1.54M
Intercept Pharmaceuticals ICPT:US $ 1.39M 29.71M
Karyopharm Therapeutics KPTI:US $ -48819000 3.32M
Macrogenics MGNX:US $ -37498000 11.07M
Mirati Therapeutics MRTX:US $ -163.78M 31.65M
Pfizer PFE:US $ 7593M 610M
Regeneron Pharmaceuticals REGN:US $ 3418.3M 2238.2M
Ultragenyx Pharmaceutical RARE:US $ -79.66M 23.55M